Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces the dosing of the first patient in the Phase IIa  clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342).  “We are excited to have the first patient enrolled and hope ...

文章核心观点 - 公司的宠物科技合作伙伴Vetbiolix已经行使了其获得完整许可协议的选择权,该协议价值3.25亿美元 [2] - Vetbiolix完成了针对犬科骨关节炎的多中心临床研究,结果显示Piclidenoson在500μg/kg剂量下可以显著改善临床状况,减轻疼痛 [3] - 犬科骨关节炎市场预计到2028年将达到30亿美元,目前市场上缺乏安全有效的治疗药物 [4] - Piclidenoson是一种创新的A3腺苷受体激动剂,在治疗银屑病的III期临床试验中已经证实了良好的安全性和疗效 [5] 公司概况 - 公司是一家处于临床晚期的生物制药公司,拥有针对癌症、肝病和炎症性疾病的创新小分子药物管线 [6] - 公司的主要药物包括用于治疗银屑病的Piclidenoson和用于治疗肝癌、非酒精性脂肪肝炎的Namodenoson [6] - 公司还有一种用于治疗勃起功能障碍的药物候选物CF602 [6] 合作伙伴情况 - 公司的宠物科技合作伙伴Vetbiolix已经获得了Piclidenoson用于治疗犬科骨关节炎的全球独家许可权 [2] - Vetbiolix将承担所有与宠物临床开发相关的费用,并向公司支付前期付款、里程碑付款和销售提成,预计未来10年内公司可获得3.25亿美元收益 [2] - Vetbiolix专注于临床前研究、CMC开发、监管性临床试验等,未来收益将来自于与宠物制药行业的出许可和/或合作开发交易 [8]

Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received approval from the Israeli Ministry of Health (MoH) to conduct Phase IIa clinical trial with orally-administered Namodenoson in the treatment of pancreatic carcinoma. "We ar ...

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for H1 2024. H1 2024 Highlights 1. Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds – in August, the Company announced the exercise of certain outstanding warrants to purchase up to an aggre ...

RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs), having an exercise price of $1.75 per ADS, issued by Can-Fite in January 2 ...

Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson, currently being developed for advanced liver cancer, pancreatic cancer and MASH. The p ...

Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson, currently being developed for advanced liver cancer, pancreatic cancer and MASH. The ...

文章核心观点 - 公司正在举办一场网络研讨会,邀请投资者参加,届时公司CEO和首席科学官将分享公司的研发管线和即将达成的里程碑 [1][2] - 公司已经获得了2000万美元的预付款和里程碑付款,这突出了其疗法的潜力 [2] - 公司的领先资产针对价值超过700亿美元的未满足的医疗需求 [2] 公司概况 - 公司是一家处于临床晚期的生物技术公司,拥有一个针对癌症、肝脏和炎症性疾病的专有小分子药物管线 [4] - 公司的主要药物候选物包括Piclidenoson和Namodenoson,已在多项临床试验中显示良好的安全性,累计超过1600名患者参与临床研究 [4] - Namodenoson已获得美国FDA的孤儿药和快速通道指定,正在进行多项临床试验,包括用于代谢相关脂肪肝炎、肝细胞癌和胰腺癌的试验 [4] - 公司第三款药物候选物CF602已显示治疗勃起功能障碍的疗效 [4]

文章核心观点 - 公司已向美国FDA提交了针对其药物候选物Namodenoson用于治疗胰腺癌的孤儿药资格申请 [1][3] - 公司计划启动一项Namodenoson的II期临床试验,评估其在晚期胰腺腺癌患者中的安全性、临床活性和药代动力学 [3] - 公司已获得Namodenoson用于治疗晚期肝癌的孤儿药资格,这进一步证实了该药物在这一严重疾病领域的潜在疗效 [3][4] 公司概况 - 公司是一家处于临床晚期的生物技术公司,拥有一个针对肿瘤、肝脏和炎症性疾病的小分子药物管线 [6] - 公司的主要药物包括用于银屑病的Piclidenoson和用于NASH、肝细胞癌及胰腺癌的Namodenoson [6] - Namodenoson已获得美国FDA和欧盟EMA的孤儿药资格认定,并获得美国FDA的快速通道资格作为肝细胞癌的二线治疗 [3][6] - 公司的第三款药物候选物CF602已显示出治疗勃起功能障碍的疗效 [6] 药物Namodenoson - Namodenoson是一种小分子口服生物利用度良好的药物,能高亲和力和选择性地结合A3腺苷受体 [5] - Namodenoson曾在II期临床试验中评估作为肝细胞癌的二线治疗和NAFLD/NASH的治疗 [5] - A3腺苷受体在疾病细胞中表达较高,而在正常细胞中表达较低,这导致该药物具有良好的安全性 [5]

PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma. An orphan drug is defined in the 1984 amendments of the U. ...